Celgene Corporation drugs
9 results
Abecma (idecabtagene vicleucel)
(idecabtagene vicleucel)Celgene Corporation
Usage: ABECMA is indicated for adult patients with relapsed or refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. It is a genetically modified autologous T cell immunotherapy targeting B-cell maturation antigen (BCMA).
Idhifa (enasidenib mesylate)
(enasidenib mesylate)Celgene Corporation
Usage: IDHIFA is indicated for treating adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-2 (IDH2) mutation, as confirmed by an FDA-approved test.
Inrebic (fedratinib hydrochloride)
(Fedratinib Hydrochloride)Celgene Corporation
Usage: INREBIC® is indicated for treating adult patients with intermediate-2 or high-risk myelofibrosis (MF), including primary or secondary forms (post-polycythemia vera or post-essential thrombocythemia).
Onureg (azacitidine)
(azacitidine)Celgene Corporation
Usage: ONUREG is indicated for the continued treatment of adult patients with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and cannot complete intensive curative therapy.
Otezla (apremilast)
(apremilast)Celgene Corporation
Usage: OTEZLA is indicated for the treatment of active psoriatic arthritis in adults, moderate to severe plaque psoriasis in candidates for phototherapy or systemic therapy, and oral ulcers associated with Behçet's Disease in adults.
Pomalyst (pomalidomide)
(pomalidomide)Celgene Corporation
Usage: POMALYST is indicated for adult patients with multiple myeloma who have undergone at least two prior therapies, including lenalidomide and a proteasome inhibitor, demonstrating disease progression. It is also indicated for treating AIDS-related Kaposi sarcoma after HAART failure and Kaposi sarcoma in HIV-negative adults.
Reblozyl (luspatercept)
(Luspatercept)Celgene Corporation
Usage: REBLOZYL is indicated for treating anemia in adult patients with beta thalassemia requiring regular RBC transfusions, anemia associated with very low- to intermediate-risk myelodysplastic syndromes (ESA-naïve), and anemia in patients with MDS-RS or MDS/MPN-RS-T failing erythropoiesis stimulating agents. It's not a substitute for immediate RBC transfusions.
Revlimid (lenalidomide)
(Lenalidomide)Celgene Corporation
Usage: REVLIMID is indicated for treating adult patients with multiple myeloma (in combination with dexamethasone), myelodysplastic syndromes associated with 5q deletion, relapsed mantle cell lymphoma, and previously treated follicular or marginal zone lymphoma (with rituximab). It is not recommended for chronic lymphocytic leukemia outside clinical trials.
Zeposia (ozanimod hydrochloride)
(ozanimod hydrochloride)Celgene Corporation
Usage: ZEPOSIA is indicated for the treatment of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) and moderately to severely active ulcerative colitis in adults.